- Home
- KNSL vs EXEL Comparison
KNSL vs EXEL Comparison
Compare KNSL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSL
- EXEL
- Stock Information
- Founded
- KNSL 2009
- EXEL 1994
- Country
- KNSL United States
- EXEL United States
- Employees
- KNSL N/A
- EXEL N/A
- Industry
- KNSL Property-Casualty Insurers
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNSL Finance
- EXEL Health Care
- Exchange
- KNSL Nasdaq
- EXEL Nasdaq
- Market Cap
- KNSL 11.0B
- EXEL 10.4B
- IPO Year
- KNSL 2016
- EXEL 2000
- Fundamental
- Price
- KNSL $455.13
- EXEL $37.16
- Analyst Decision
- KNSL Buy
- EXEL Buy
- Analyst Count
- KNSL 10
- EXEL 21
- Target Price
- KNSL $506.44
- EXEL $43.65
- AVG Volume (30 Days)
- KNSL 185.3K
- EXEL 2.4M
- Earning Date
- KNSL 10-23-2025
- EXEL 10-28-2025
- Dividend Yield
- KNSL 0.15%
- EXEL N/A
- EPS Growth
- KNSL 20.44
- EXEL 81.76
- EPS
- KNSL 19.16
- EXEL 2.08
- Revenue
- KNSL $1,723,392,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- KNSL $15.65
- EXEL $9.24
- Revenue Next Year
- KNSL $9.31
- EXEL $13.04
- P/E Ratio
- KNSL $23.76
- EXEL $17.77
- Revenue Growth
- KNSL 21.12
- EXEL 10.73
- 52 Week Low
- KNSL $405.00
- EXEL $25.12
- 52 Week High
- KNSL $531.79
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- KNSL 49.52
- EXEL 38.33
- Support Level
- KNSL $447.09
- EXEL $37.71
- Resistance Level
- KNSL $462.10
- EXEL $38.95
- Average True Range (ATR)
- KNSL 10.05
- EXEL 0.85
- MACD
- KNSL 1.48
- EXEL 0.13
- Stochastic Oscillator
- KNSL 57.96
- EXEL 33.91
About KNSL Kinsale Capital Group Inc.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.